MADRIGAL PHARMACEUTICALS INC (MDGL)

Madrigal Pharmaceuticals (NASDAQ:MDGL - Get Free Report) issued its quarterly earnings data on Thursday. The biopharmaceutical company reported ($1.99) EPS for the quarter, beating analysts' consensus estimates of ($2.68) by $0.69. Madrigal Pharmaceuticals had a negative return on equity of ...

Prefer clean charts over scrolling through walls of earnings tables and cash flow figures? Get a clear visual read on Madrigal Pharmaceuticals, including how its valuation compares with its current loss making profile, in the full company report for Madrigal Pharmaceuticals. NasdaqGS:MDGL Trailing .…

Madrigal Pharmaceuticals (MDGL) drew attention after its second quarter 2026 earnings release, which highlighted Rezdiffra sales growth, stronger patient uptake, a smaller than expected quarterly loss, and revenue ahead of market estimates. See our latest analysis for Madrigal Pharmaceuticals.

Checkout Madrigal Pharmaceuticals Inc (MDGL) earnings results, EPS expectations and actual EPS values for both quarterly and annual periods. Discover whether MDGL beat the street expectations or not?

Calendar & Research Financial Calendar Earnings Calendar & Reports Analyst Ratings Fund Letters Archive Transcripts Search Stock Market Holidays ... On July 30, 2026, Madrigal Pharmaceuticals Inc (NASDAQ: MDGL) reported a robust 71% year-over-year increase in net sales for the second quarter ...